← Leaderboards
Binsheng Zhao
Columbia University Health Sciences
$4,755,628
Attributed
$7,819,955
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2011–22$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$7,571,341 · 3
FDA$248,614 · 1
By mechanism
U01$6,128,654 · 3
R01$1,691,301 · 1
Top collaborators
- Lawrence H Schwartz11 shared
- Ying Tang1 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- R Graham Barr$40,525,821
- Benjamin M. Smith$6,172,371
- Alexandre R. Franco$1,033,425
- Raul Rabadan$24,791,435
- Thomas L. Nickolas$5,747,594
Others in their field
Top investigators on “Measurement”
- Lawrence Corey · Fred Hutchinson Cancer Center$517,278,507
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$468,973,477
- David R. Weir · University Of Michigan At Ann Arbor$403,695,976
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$297,689,086
- Christopher McKay · Battelle Memorial Institute$290,340,771
- David H Reitze · University Of Florida$256,180,831
Research focus
MeasurementBaseTumor VolumeMutationResponseImaging ModalityClinical TrialsEpidermal Growth Factor ReceptorNon-Small-Cell Lung CarcinomaDrug DiscoveryFollow-UpFutureImageImage AnalysisTumorClinical PracticeX-Ray Computed TomographyAlgorithmsHome EnvironmentBiological MarkersClinical DataEvaluationComputersCancer And Leukemia Group B
Grant awards (18)
Integrating Radiomics into S0819 and Lung-MAP, Biomarker Driven Clinical Trials for Lung Cancer$566,084
U01 · FY2022 · CA
DDTBMQ000011: Advance tumor volume change as measured by CT as a pharmacodynamic biomarker for new oncologic drug clinical trial therapy of solid tumors to Stage 2 of FDA biomarker qualification$248,614
U01 · FY2022 · FD
Integrating Radiomics into S0819 and Lung-MAP, Biomarker Driven Clinical Trials for Lung Cancer$31,210
U01 · FY2022 · CA
Integrating Radiomics into S0819 and Lung-MAP, Biomarker Driven Clinical Trials for Lung Cancer$609,495
U01 · FY2021 · CA
Integrating Radiomics into S0819 and Lung-MAP, Biomarker Driven Clinical Trials for Lung Cancer$609,531
U01 · FY2020 · CA
Integrating Radiomics into S0819 and Lung-MAP, Biomarker Driven Clinical Trials for Lung Cancer$601,400
U01 · FY2019 · CA
Integrating Radiomics into S0819 and Lung-MAP, Biomarker Driven Clinical Trials for Lung Cancer$644,727
U01 · FY2018 · CA
Studying measurement variability in tumor volume and volume change on MDCT$223,578
R01 · FY2016 · CA · contact PI
Quantitative Volume and Density Response Assessment: Sarcoma and HCC as a Model$520,335
U01 · FY2015 · CA
Studying measurement variability in tumor volume and volume change on MDCT$263,957
R01 · FY2015 · CA · contact PI
Quantitative Volume and Density Response Assessment: Sarcoma and HCC as a Model$520,533
U01 · FY2014 · CA
Studying measurement variability in tumor volume and volume change on MDCT$186,332
R01 · FY2014 · CA · contact PI
Quantitative Volume and Density Response Assessment: Sarcoma and HCC as a Model$536,959
U01 · FY2013 · CA
Studying measurement variability in tumor volume and volume change on MDCT$321,127
R01 · FY2013 · CA · contact PI
Quantitative Volume and Density Response Assessment: Sarcoma and HCC as a Model$583,741
U01 · FY2012 · CA
Studying measurement variability in tumor volume and volume change on MDCT$341,345
R01 · FY2012 · CA · contact PI
Quantitative Volume and Density Response Assessment: Sarcoma and HCC as a Model$656,025
U01 · FY2011 · CA
Studying measurement variability in tumor volume and volume change on MDCT$354,962
R01 · FY2011 · CA · contact PI